[go: up one dir, main page]

MXPA03003032A - Terapia de combinacion para el tratamiento de una enfermedad sensible a los estrogenos. - Google Patents

Terapia de combinacion para el tratamiento de una enfermedad sensible a los estrogenos.

Info

Publication number
MXPA03003032A
MXPA03003032A MXPA03003032A MXPA03003032A MXPA03003032A MX PA03003032 A MXPA03003032 A MX PA03003032A MX PA03003032 A MXPA03003032 A MX PA03003032A MX PA03003032 A MXPA03003032 A MX PA03003032A MX PA03003032 A MXPA03003032 A MX PA03003032A
Authority
MX
Mexico
Prior art keywords
estrogen
treatment
combination therapy
sensitive disease
disease
Prior art date
Application number
MXPA03003032A
Other languages
English (en)
Inventor
S Mark Moran
Original Assignee
Biomedicines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomedicines Inc filed Critical Biomedicines Inc
Publication of MXPA03003032A publication Critical patent/MXPA03003032A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MXPA03003032A 2000-10-06 2001-10-03 Terapia de combinacion para el tratamiento de una enfermedad sensible a los estrogenos. MXPA03003032A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23877200P 2000-10-06 2000-10-06
PCT/US2001/031060 WO2002030429A1 (en) 2000-10-06 2001-10-03 Combination therapy for the treatment of estrogen-sensitive disease

Publications (1)

Publication Number Publication Date
MXPA03003032A true MXPA03003032A (es) 2003-06-06

Family

ID=22899242

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03003032A MXPA03003032A (es) 2000-10-06 2001-10-03 Terapia de combinacion para el tratamiento de una enfermedad sensible a los estrogenos.

Country Status (14)

Country Link
US (5) US20020119502A1 (es)
EP (1) EP1330251A4 (es)
JP (1) JP2004510994A (es)
CN (1) CN1471400A (es)
AU (1) AU2001296578A1 (es)
BR (1) BR0114655A (es)
CA (1) CA2424299A1 (es)
HU (1) HUP0301276A2 (es)
IL (1) IL155237A0 (es)
MX (1) MXPA03003032A (es)
NZ (1) NZ525105A (es)
PL (1) PL361874A1 (es)
RU (1) RU2003112974A (es)
WO (1) WO2002030429A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA03010401A (es) * 2001-05-16 2004-03-09 Novartis Ag Combinacion que comprende n-[5-[4- (4-metil- piperazino-metil) -benzoilamido] -2-metilfenil] -4-(3-piridil)-2 -pirimidin-amina, y un agente quimioterapeutico.
US6967194B1 (en) * 2002-09-18 2005-11-22 Susan Matsuo Bio-identical hormones and method of use
SE0401790D0 (sv) * 2004-07-07 2004-07-07 Forskarpatent I Syd Ab Tamoxifen response in pre- and postmenopausal breast cancer patients
EP1623713A1 (en) * 2004-07-09 2006-02-08 Proskelia SAS Cominations of pure anti-estrogen with aromatase inhibitors
WO2011002096A1 (ja) * 2009-07-03 2011-01-06 独立行政法人理化学研究所 Ｐｅｔ用標識化合物
RU2413546C1 (ru) * 2009-09-17 2011-03-10 Учреждение Российской академии медицинских наук Российский онкологический научный центр имени Н.Н. Блохина РАМН (РОНЦ им. Н.Н. Блохина РАМН) Способ лечения экстраабдоминальных десмоидных опухолей
EP2580210B1 (en) 2010-06-10 2017-03-01 Seragon Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof
EP2791132A4 (en) 2011-12-14 2015-08-05 Seragon Pharmaceuticals Inc ESTROGEN RECEPTOR MODULATORS AND USES THEREOF
EP3384282A1 (en) * 2015-11-30 2018-10-10 Pharnext Method for adapting doses of combination therapies

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4760053A (en) * 1984-08-02 1988-07-26 Fernand Labrie Combination therapy for selected sex steroid dependent cancers
US5064813A (en) * 1984-08-02 1991-11-12 Fernand Labrie Combination therapy for selected sex steroid dependent cancers
US4775660A (en) * 1984-08-02 1988-10-04 Fernand Labrie Treatment of breast cancer by combination therapy
US4666885A (en) * 1985-02-08 1987-05-19 Fernand Labrie Combination therapy for treatment of female breast cancer
US5023234A (en) * 1985-02-08 1991-06-11 Fernand Labrie Combination male breast cancer therapy
DE3733478A1 (de) * 1987-10-01 1989-04-13 Schering Ag Antigestagen- und antioestrogenwirksame verbindungen zur geburtseinleitung und zum schwangerschaftsabbruch sowie zur behandlung gynaekologischer stoerungen und hormonabhaengiger tumore
EP0462189B1 (en) * 1989-03-10 1995-09-27 Endorecherche Inc. Combination therapy for treatment of estrogen sensitive diseases
GB9207437D0 (en) * 1992-04-03 1992-05-20 Orion Yhtymae Oy Topical administration of toremifene and its metabolites

Also Published As

Publication number Publication date
US20050228053A1 (en) 2005-10-13
US20050176691A1 (en) 2005-08-11
PL361874A1 (en) 2004-10-04
EP1330251A4 (en) 2006-03-15
CN1471400A (zh) 2004-01-28
RU2003112974A (ru) 2004-11-27
AU2001296578A1 (en) 2002-04-22
JP2004510994A (ja) 2004-04-08
HUP0301276A2 (hu) 2003-11-28
EP1330251A1 (en) 2003-07-30
CA2424299A1 (en) 2002-04-18
US20050130945A1 (en) 2005-06-16
WO2002030429A1 (en) 2002-04-18
BR0114655A (pt) 2004-02-10
US20020119502A1 (en) 2002-08-29
US20050232862A1 (en) 2005-10-20
NZ525105A (en) 2004-10-29
IL155237A0 (en) 2003-11-23

Similar Documents

Publication Publication Date Title
AP2004003002A0 (en) azabicyclic-substituted fused-heteroaryl compoundsfor the treatment of disease.
IL159344A0 (en) Quinuclidines-substituted-multicyclic-heteroaryls for the treatment of disease
IL196301A0 (en) Medicament for the treatment of hapatitis c
MXPA03001419A (es) Combinacion terapeutica de un inhibidor de la proteina de transferencia de esteres de colesterol y atorvastatina.
ZA200305126B (en) Methods of administering epothilone analogs for the treatment of cancer.
AP2003002842A0 (en) Phenethanolamine derivatives for treatment of respiratory disease.
IL150742A0 (en) Pyridopyrimidinone derivatives for the treatment of neurodegenerative disease
IL151890A0 (en) Hydroxyphenyl-piperidin 4-ylidene-methyl-benzamide derivatives for the treatment of pain
ZA200108905B (en) Use of macrolide compounds for the treatment of dry eye.
ZA200307475B (en) Carbamate compounds for use in the treatment of pain.
MXPA03006776A (es) Uso de inhibidores de interleucina-18 para el tratamiento y/o prevencion de enfermedad cardiaca.
IL151765A0 (en) Hydroxyphenyl-piperazinyl-methyl-benzamide derivatives for the treatment of pain
IL151891A0 (en) Quinolinyl-piperidin 4-ylidene-methyl-benzamide derivatives for the treatment of pain
MXPA03003032A (es) Terapia de combinacion para el tratamiento de una enfermedad sensible a los estrogenos.
GB0001710D0 (en) Therapeutic treatment
MXPA03006412A (es) Metodos para administrar analogos de epotilona para tratamiento de cancer.
IL142581A (en) Medicament for treating heart disease
AU2096002A (en) Therapeutic treatment
GB0029524D0 (en) Disease treatment
ZA200203166B (en) Treatment of cancer.
GB0128628D0 (en) Disease treatment
AP2004003014A0 (en) Use of specific dose of fondaparinux sodium for the treatment of ACS.
GB2397018B (en) Combination therapy for treating disease
HK1057996A (en) Combination therapy for the treatment of estrogen-sensitive disease
ZA200308844B (en) Quinuclidines-substituted-multi-cyclic-heteroaryls for the treatment of disease.